Abstract:A long-standing challenge is how to formulate proteins and vaccines to retain function during storage and transport and to remove the burdens of cold-chain management. Any solution must be practical to use, with the protein being released or applied using clinically relevant triggers. Advanced biologic therapies are distributed cold, using substantial energy, limiting equitable distribution in low-resource countries and placing responsibility on the user for correct storage and handling. Cold-chain management is the best solution at present for protein transport but requires substantial infrastructure and energy. For example, in research laboratories, a single freezer at -80 °C consumes as much energy per day as a small household1. Of biological (protein or cell) therapies and all vaccines, 75% require cold-chain management; the cost of cold-chain management in clinical trials has increased by about 20% since 2015, reflecting this complexity. Bespoke formulations and excipients are now required, with trehalose2, sucrose or polymers3 widely used, which stabilize proteins by replacing surface water molecules and thereby make denaturation thermodynamically less likely; this has enabled both freeze-dried proteins and frozen proteins. For example, the human papilloma virus vaccine requires aluminium salt adjuvants to function, but these render it unstable against freeze-thaw4, leading to a very complex and expensive supply chain. Other ideas involve ensilication5 and chemical modification of proteins6. In short, protein stabilization is a challenge with no universal solution7,8. Here we designed a stiff hydrogel that stabilizes proteins against thermal denaturation even at 50 °C, and that can, unlike present technologies, deliver pure, excipient-free protein by mechanically releasing it from a syringe. Macromolecules can be loaded at up to 10 wt% without affecting the mechanism of release. This unique stabilization and excipient-free release synergy offers a practical, scalable and versatile solution to enable the low-cost, cold-chain-free and equitable delivery of therapies worldwide.

A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform for On-Demand Production of Conjugate Vaccines

Mechanical release of homogenous proteins from supramolecular gels

Determination of Conformational and Functional Stability of Potential Plague Vaccine Candidate in Formulation

A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Cell-free protein synthesis: Applications come of age

Development Of A Robust Escherichia Coli-Based Cell-Free Protein Synthesis Application Platform

Strategy Exploration for Developing Robust Lyophilized Cell-Free Systems

Heat Stable and Intrinsically Sterile Liquid Protein Formulations

A Cost-Effective Pichia pastoris Cell-Free System Driven by Glycolytic Intermediates Enables the Production of Complex Eukaryotic Proteins

Photothermal heating of cell-free reactions for on-site production of recombinant proteins

Pichia pastoris (Komagataella phaffii) as a Cost-Effective Tool for Vaccine Production for Low- and Middle-Income Countries (LMICs)

Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine

A Scalable Synthesis of Adjuvanting Antigen Depots Based on Met-al-Organic Frameworks

Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines

A novel method for synthetic vaccine construction based on protein assembly

Stabilization of HAC1 influenza vaccine by spray drying: formulation development and process scale-up

Conformation-Stabilized Amorphous Nanocoating for Rational Design of Long-Term Thermostable Viral Vaccines

Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection

Formulation Development of a COVID-19 Recombinant Spike Protein-Based Vaccine

Decoupling Fluorous Protein Coatings Yield Heat-Stable and Intrinsically Sterile Bioformulations

On-demand manufacturing of clinical-quality biopharmaceuticals